天津医药 ›› 2021, Vol. 49 ›› Issue (3): 285-290.doi: 10.11958/20201714

• 临床研究 • 上一篇    下一篇

循环microRNA-223水平与急性冠脉综合征患者的血小板反应及临床预后相关性的研究

张莹莹1,郭绪昆1,郑君毅1,刘婷2,张莹2,马静2,刘寅1   

  1. 1天津市胸科医院心内科(邮编300222);2天津市心血管病研究所
  • 收稿日期:2020-06-18 修回日期:2020-12-30 出版日期:2021-03-15 发布日期:2021-03-15
  • 作者简介:张莹莹(1977),女,博士,副主任医师,主要从事心血管疾病临床及基础研究。E-mail:1424413836@qq.com

Correlation research between circulating microRNA-223 and platelet activity and prognosis in patients with acute coronary syndrome

ZHANG Ying-ying1, GUO Xu-kun1, ZHENG Jun-yi1, LIU Ting2, ZHANG Ying2, MA Jing2, LIU Yin1   

  1. 1 Department of Cardiology, Tianjin Chest Hospital, Tianjin 300222, China; 2 Tianjin Institute of Cardiovascular Disease
  • Received:2020-06-18 Revised:2020-12-30 Published:2021-03-15 Online:2021-03-15

摘要: 目的 研究血浆microRNA-223(miR-223)表达水平与急性冠脉综合征(ACS)患者服用氯吡格雷后血小板反应及临床预后的关系。方法 连续纳入接受经皮冠状动脉介入治疗(PCI)的ACS患者208例,术前均接受负荷剂量的氯吡格雷+阿司匹林的双联抗血小板聚集治疗(DAPT)。采用实时荧光定量PCR(qPCR)检测血浆miR-223表达水平,流式细胞术检测血小板反应指数(PRI)。根据PRI中位数将患者分为低PRI组(PRI≤56.3%)和高PRI组(PRI>56.3%),各104例。比较2组患者血浆miR-223表达水平和主要临床及生化指标。随访2年,通过Cox比例风险回归分析血浆miR-223表达水平、PRI、肌钙蛋白I(TnI)、B型钠尿肽(BNP)等指标对主要不良心血管事件(MACE)的影响因素。通过受检者工作特征(ROC)曲线评价血浆miR-223、PRI对MACE的预测能力。结果 miR-223表达水平与PRI呈负相关(rs=-0.420,P<0.05)。低PRI组患者血浆miR-223表达水平高于高PRI组[(1.15(0.58,1.80) vs. 0.64(0.26,1.08),Z=0.471,P<0.05]。30例(14.4%)患者发生MACE,低PRI组MACE发生率低于高PRI组(P<0.05)。Cox比例风险回归分析显示,血浆miR-223和PRI是ACS患者发生MACE的独立预测因子。血浆miR-223和PRI预测ACS患者发生MACE的ROC曲线下面积分别为0.700(95%CI:0.609~0.791,P<0.05)和0.710(95%CI:0.606~0.815,P<0.05)。结论 循环miR-223表达水平与ACS患者服用氯吡格雷后PRI呈负相关,循环miR-223和PRI是ACS患者PCI术后MACE的独立预测因子。

关键词: 急性冠状动脉综合征, 血小板聚集抑制剂, 微RNAs, miR-223, 氯吡格雷, 血小板反应指数, 双联抗血小板治疗

Abstract: Objective To investigate the relationship between the expression level of plasma microRNA-223 (miR-223) and platelet reactivity as well as clinical prognosis in patients with acute coronary syndrome (ACS) after clopidogrel administration. Methods A total of 208 ACS patients received percutaneous coronary intervention (PCI) were enrolled consecutively. All patients were treated with loading doses of clopidogrel combined with aspirin (DAPT) before intervention. Real-time PCR was used to quantify the expression level of plasma miR-223, and the platelet reactive index (PRI) was quantified through flow cytometry. Patients were divided into two groups according to the PRI median, low PRI group (PRI≤56.3%) and high PRI group (PRI>56.3%), with 104 cases in each group. Plasma miR-223 expression levels, basic clinical data and biochemical index were compared between two groups of patients. After 2-year follow-up, Cox proportional risk regression analysis was used to estimate the influencing factors of plasma miR-223 level, PRI, troponin I (TnI), B-type natriuretic peptide (BNP) and other parameters for major adverse cardiovascular events (MACE). The receiver operating characteristic (ROC) curve was plotted to evaluate the predictive ability of plasma miR-223 and PRI levels for MACE. Results The level of circulating miR-223 was negatively correlated with PRI (rs=-0.420, P<0.05), and miR-223 expression level was significantly higher in low PRI group compared with that of high PRI group [1.15 (0.58,1.80) vs.0.64 (0.26,1.08), Z=0.471, P<0.05]. MACE occurred in 30 patients (14.4%), and the incidence of MACE was lower in low PRI group than that in high PRI group (P < 0.05). Cox proportional risk regression analysis showed that the plasma miR-223 level and PRI were independent risk factors for predicting MACE in ACS patients. The AUC of plasma miR-223 and PRI for predicting the occurrence of MACE in ACS patients was 0.700 (95%CI: 0.609-0.791, P<0.05) and 0.710 (95%CI: 0.606-0.815, P<0.05), respectively. Conclusion The circulating miR-223 level is negatively correlated with PRI in ACS patients after taking clopidogrel. The circulating miR-223 level and PRI are independent factors for predicting MACE in ACS patients after PCI.

Key words: acute coronary syndrome, platelet aggregation inhibitors, microRNAs, miR-223, clopidogrel, platelet reactive index, dual antiplatelet therapy